This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .

Post-Test - Peak Issues (Issue 4): Clinical Use Of Incretin-Based Therapies To Treat Type 2 Diabetes

INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.

1.	Individuals with type 2 diabetes (T2DM) are ____ times more likely to die from heart disease than adults without diabetes.
A:		2
B:		3
C:		4
D:		5

2.	The ACCORD trial studied the effects of tight glycemic control on cardiovascular risk reduction. The trial showed a significant reduction for cardiovascular risk in the intensive group.
A:		True
B:		False

3.	In a 2009 meta-analysis, Mannuci et al showed an increased risk of cardiovascular risk associated with this condition in the intensive group:
A:		Hyperlipidemia
B:		Hyperglycemia
C:		Hypoglycemia
D:		Hypertension

4.	Which of the following actions does NOT contribute to postprandial hyperglycemia in T2DM patients?
A:		Impaired suppression of glucagon
B:		Impaired incretin effect
C:		Delayed gastric emptying
D:		Hepatic glucose production

5.	At an A1C of 7.1%, which glycemic indicator contributes most substantially to overall hyperglycemia?
A:		Fasting plasma glucose (FPG)
B:		Postprandial glucose (PPG)

6.	The incretin hormones, GLP-1 and GIP, are thought to contribute up to ___ of postprandial insulin secretion.
A:		30%
B:		60%
C:		70%
D:		90%

7.	Which of the following is true regarding DPP-4 inhibitors?
A:		DPP-4 inhibitors have not been evaluated for monotherapy treatment of T2DM
B:		DPP-4 inhibitors have no significant effect on PPG
C:		DPP-4 inhibitors have a side effect profile comparable to placebo
D:		DPP-4 inhibitors typically result in up to a 5 kg weight loss

8.	Which of the following is a short-acting GLP-1 agonist?
A:		Exenatide
B:		Exenatide LAR
C:		Liraglutide
D:		Taspoglutide
E:		All of the above

9.	"Hypoglycemic unawareness" is more likely to occur with:
A:		Higher A1C
B:		Increasing age
C:		Higher diabetes knowledge
D:		α-blocker therapy

10.	Which of the following is correct regarding the recent AACE/ACE guidelines updates?
A:		The guidelines recommend selection of agents primarily based on cost due to spiraling diabetes healthcare costs
B:		Conservative escalation of therapy due to the risk of hypoglycemia
C:		Early use of GLP-1 receptor agonists due to their effect on β-cell function
D:		GLP-1 receptor agonist use over DPP-4 inhibitors due to their superior effect on postprandial glucose